SPHK2

Across TCGA pan-cancer cohorts, SPHK2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SPHK2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SPHK2 RNA is repressed in tumor relative to normal tissue. In most cancer types SPHK2 is over-expressed in tumor, although a few such as KIRC and THCA show the opposite, repressed pattern.

KIRC, THCA, and KICH are the cancer types where SPHK2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPHK2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	−1.051	<.001	11	view →
THCA	Male	III,IV	−0.877	<.001	11	view →
KICH	Male	All	−1.260	<.001	10	view →
KIRP	Male	III,IV	−1.116	<.001	9	view →
BRCA	All	II,III,IV	+0.187	.016	8	view →
HNSC	Male	III,IV	+0.569	<.001	7	view →
STAD	All	II,III,IV	+0.857	.001	6	view →
UCEC	All	All	+0.448	.024	4	view →
CHOL	All	All	+0.965	.001	3	view →
PAAD	All	All	+0.512	.029	2	view →
LIHC	Female	All	+0.494	.018	2	view →
PRAD	All	All	+0.194	.036	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SPHK2–KIRC

Open the KIRC breakdown →